Background: A relationship was observed between cholesterol and the development of many cancer types. However, the efficacy of the addition of hypolipidimic medications to cancer treatment regimen is unclear. Objective: To study the possible effects of atorvastatin on Ehrlich solid tumor bearing mice treated with cisplatin and to explore atorvastatin effects on inflammation and oxidative stress. Materials and methods: Sixty female Swiss albino mice were divided into five equal groups: Negative control, positive control, cisplatin treated, atorvastatin-treated and combination of cisplatin-and atorvastatin-treated group. Tumor volume, total antioxidant capacity, catalase, malondialdehyde, C-reactive protein and angiogenin were determined. Results: Markers of oxidative stress were the worest in cisplatin-treated group and the best in combination-treated group as there was significant increase in serum catalase and a relative increase in serum total antioxidant capacity (TAC) than cisplatin treated group. Moreover, serum malondialdehyde (MDA) showed relative decrease in combination-treated group than cisplatin-treated group.  Conclusion: The use of atorvastatin/cisplatin combination therapy increased antioxidant enzymes and decreased cisplatin induced oxidative stress pointing at the antioxidant effect of atorvastatin as a possible mechanism for its anticancer activity